Catalent Invests $5.5 Million to Increase Clinical Storage Capacity at its Philadelphia Site
SOMERSET, N.J.-September 15, 2017
-Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it is investing $5.5 million at its 200,000+ square foot Philadelphia, Pennsylvania site to provide additional clinical packaging and storage capacity. The 22,000-square foot expansion will see a 40 percent increase in pallet space for both refrigerated and ambient storage, the addition of multiple cold chain packaging areas, and a new clinical label control area. The building will also feature a new state-of-the-art environmental monitoring and building management system which is being installed across the Philadelphia campus. All work is scheduled to be completed and validated by November 2017. “This project involved renovating a previously vacant building within our Philadelphia campus to bring it up to Catalent’s stringent facility standards,” commented Wetteny Joseph, Catalent’s President, Clinical Supply Services. “Not only have we added significant pallet capacity for our customers’ large-scale clinical studies today, but have secured the space necessary for future expansion as well.” Catalent currently supports the clinical trial supply needs of many pharmaceutical and biopharmaceutical organizations, including the top 25 pharmaceutical companies, and more than 300 small innovators from all over the world. Services include direct comparator sourcing, blinding and manufacturing, primary and secondary packaging, returns and clinical supplies management.
About Catalent
Catalent is a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit
www.catalent.com
More products. Better treatments. Reliably supplied.™
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
